Deficient activation of CB95 (APO-1/Fas) mediated apoptosis: A potential factor of multidrug resistance in human renal cell carcinoma

British Journal of Cancer

Volumn 82, Issue 11, 2000, Pages 1851-1859

  Ramp, U ^a   Dejosez, M ^a   Mahotka, C ^a   Czarnotta, B ^a   Kalinski, T ^a   Wenzel, M ^a   Lorenz, I ^a   Muller M ^b   Krammer, P ^c   Gabbert, H E ^a   Gerharz, C D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer drugs; Apoptosis; CD95 (APO 1 Fas); Multidrug resistance; Renal cell carcinoma

Indexed keywords

BLEOMYCIN; DNA TOPOISOMERASE INHIBITOR; FAS ANTIGEN; GLYCOPROTEIN P; PROTEIN P21; PROTEIN P53; TOPOTECAN; ANTINEOPLASTIC AGENT; LIGAND; PRIMER DNA;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EXON; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; KIDNEY TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, RENAL CELL; DNA PRIMERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENES, P53; HUMANS; KIDNEY NEOPLASMS; LIGANDS; MUTATION; TUMOR CELLS, CULTURED;

EID: 0033625764     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Baldini N (1997) Multidrug resistance - a multiplex phenomenon. Nat Med 3: 78-380
2. Caignard A, Guillard M, Cai C, Asselin-Paturel C, Carayol G and Chouaib S (1996) The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Tissue Antigens 48: 295-300
3. Cascino I, Fiucci G, Pappoff G and Ruberti G (1995) Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154: 2700-2713
4. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF-1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
5. Friesen C, Herr I, Krammer PH and Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577
6. Friesen C, Fulda S and Debatin KM (1997) Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11: 1833-1841
7. Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823-3829
8. Fulda S, Los M, Friesen C and Debatin KM (1998) Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76: 105-114
9. Gerharz CD, Moll R, Störkel S, Ramp U, Thoenes W and Gabbert HE (1993) Ultrastructural appearance and cytoskeletal architecture of the clear cell, chromophilic and chromophobe cell variants of human renal cell carcinoma in vivo and in vitro. Am J Pathol 142: 851-859
10. Gerharz CD, Ramp U, Olert J, Moll R, Störkel S, Marx N and Gabbert HE (1994) Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type. Virchows Arch B 424: 403-409
11. Gerharz CD, Moll R, Störkel S, Ramp U, Hildebrandt B, Molsberger G, Koldovsky P and Gabbert HE (1995) Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. Am J Pathol 146: 953-962
12. Gerharz CD, Hilderbrandt B, Moll R, Ramp U, Sarbia M, Störkel S, Koldovsky P and Gabbert HE (1996) Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterization of four permanent cell lines. Br J Cancer 74: 1605-1614
13. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318-1327
14. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
15. Herben VMM, ten Bokkel Huinink WW and Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31: 85-102
16. Hetts SW (1998) To die or not to die. An overview of apoptosis and its role in disease. JAMA 279: 300-307
17. Hickman JA (1992) Apotosis induced by anti-cancer agents. Cancer Metastasis Rev 11: 121-139
18. Homma Y and Aso Y (1994) Effect of α-Interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol 25: 164-170
19. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kakizoe T and Kawabe K (1997) Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol 27: 384-388
20. Keane MM, Ettenberg SA, Lowrey GA, Russel EK and Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56: 4791-4798
21. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMBO J 14: 5579-5588
22. Krammer PH (1997) The tumor strikes back. New data on expression of the CD95 (APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differentiation 4: 362-364
23. Mickisch GH, Bier H, Bergler W, Bak M, Tschada R and Alken P (1990) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 45: 170-176
24. Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H and Sato K (1995) A new water-soluble camptothecin derivate, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86: 776-782
25. Miyake H, Hara I, Gohji K, Arakawa S and Kamidono S (1998) p53 modulation of Fas/APO-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol 12: 469-473
26. Moll UM and Schramm LM (1998) p53 - an acrobat in tumorigenesis. Crit Rev Oral Biol Med 9: 23-37
27. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-64
28. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W and Belldegrun A (1997) Renal cell carcinoma: recent progress and future directions. Cancer Res 57: 5189-5195
29. Muller M, Strand S, Hug H, Heinemann EM, Walezak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413
30. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M and Krammer PH (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 11: 2033-2045
31. Nagata S (1994) Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci 345: 281-287
32. Nakajima H, Yamada N and Takiguchi M (1998) Fas-independent apoptosis of T cells via killer cell inhibitory receptors. Int Immunol 10: 85-90
33. Natoli G, Ianni A, Constanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C and Levrero M (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11: 1157-1164
34. Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nihimura K, Kojima Y and Okuyama A (1996) Fas/APO-1 mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun 229: 945-951
35. O'Connell J, O'Sullivan GC, Collins JK and Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082
36. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E and Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce FAS/APO-1 expression. Mol Cell Biol 15: 3032-3040.
37. Peter ME, Dhen I, Ehret A, Helbardt S, Walczak H, Moldenhauer G and Krammer PH (1995) APO-1 (CD95)-dependent and independent antigen-receptor-induced apoptosis in human T and B cell lines. Int Immunol 7: 1873-1877
38. 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 76: 739-749
39. Reiter RE, Anglard P, Liu S, Gnarra JR and Linnehan WM (1993) Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53: 3092-3097
40. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME (1998) Two CD95 (APO-1/Fas) signalling pathways. EMBO J 17: 1675-1687
41. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH and von Hoff DD (1986) Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treatment Reports 70: 1379-1382
42. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME (1998) Apoptosis signalling by death receptors. Eur J Biochem 254: 439-459
43. Sorensen M, Sehested M and Jensen PB (1995) Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72: 399-404
44. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 2: 1361-1366
45. Tomita Y, Kawasaki T, Bilim V, Takeda M and Takahashi K (1996) Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/APO-1 (CD95)-mediated apoptosis in renal cancer cells. Int J Cancer 68: 132-135
46. Waldman T, Kinzler KW and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190
47. Webb JL (1963) Effects of more than one inhibitor. In: Enzyme and Metabolic Inhibitors. Vol 1, pp. 487-512. Academic Press: New York.